Iuliana Shapira, MD is Chief Medical Officer at Regional Cancer Care Associates. She oversees clinical operations which includes quality of care and patient safety, coordination of clinical care, development of clinical information support systems, and physician engagement in strategic initiatives to provide value-based quality care. Her role also includes overseeing and expanding the research portfolio and implementation of innovative programs to advance quality improvement and new models of care for best practices in oncology.
Dr. Shapira comes to RCCA from State University of New York in Brooklyn, New York, where she held the position of Chief of Division of Hematology Oncology and Director of Cancer Institute at State University New York (SUNY) Downstate Medical Center. During her tenure at Downstate, she introduced changes that lead to major improvements in the safety and quality of care and mentored numerous physicians, residents and medical students. As a member of the Medical Executive Committee at SUNY Downstate she has contributed to the development and implementation of the corporate strategy. Earlier, she worked for nine years as Director of Cancer Genetics at Northwell Health System and Associate Professor of Medicine at Hofstra University.
Dr. Shapira holds the academic appointment as Associate Professor of Medicine and Cell Biology for the SUNY Downstate Medical Center in Brooklyn, New York. Prior to her work in academic medicine, Dr. Shapira served in clinical practice in rural Lake Village, Arkansas. She received her medical degree in 1990 from the Carol Davila Medical School in Bucharest. She conducted her residency training in Internal Medicine at St. Barnabas Medical Center in Livingston, New Jersey and Hematology Oncology Fellowship at SUNY Downstate Medical Center.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.